Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial

European Neuropsychopharmacology

Volumn 14, Issue 6, 2004, Pages 457-470

  Detke, Michael J ^a,b,c,d   Wiltse, Curtis G ^a   Mallinckrodt, Craig H ^a   McNamara, Robert K ^a   Demitrack, Mark A ^e   Bitter, Istvan ^f  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCLEAN HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Neuronetics Inc   (United States)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antidepressant; Anxiety; Duloxetine; Efficacy tolerability; HAMD17; MDD; Pain; Physical symptoms; Safety

Indexed keywords

DULOXETINE; PAROXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT WITHDRAWAL; VIRUS INFECTION; VISUAL ANALOG SCALE; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY WEIGHT; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; THIOPHENES;

EID: 10344219954     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.01.002     Document Type: Article

References (78)

1. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58:2000;19-36
2. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv. Rev. Psychiatry. 7:2000;257-277
3. Bakish D. New standard of depression treatment: remission and full recovery. J. Clin. Psychiatry. 62(Suppl. 26):2001;5-9
4. Barsky A.J., Wyshak G., Klerman G.L. Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients. Arch. Gen. Psychiatry. 43:1986;493-500
5. Beasley C.M. Jr., Koke S.C., Nilsson M.E., Gonzales J.S. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin. Ther. 22:2000;1319-1330
6. Bjelland I., Dahl A.A. Anxiety and depression - a common mixture. Tidsskr. Nor. Laegeforen. 119:1999;3277-3280
7. Bonierbale M., Lancon C., Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr. Med. Res. Opin. 19:2003;114-124
8. Brannan S.K., Detke M.J., Wang F., Mallinckrodt C.H., Watkin J.G., Tran P.V., Delgado P.L. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: acute- and long-term data. Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2003:2003
9. Chalon S.A., Granier L.A., Vandenhende F.R., Bieck P.R., Bymaster F.P., Joliat M.J., Hirth C., Potter W.Z. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 28:2003;1685-1693
10. Cornwall P.L., Scott J. Partial remission in depressive disorders. Acta Psychiatr. Scand. 95:1997;265-271
11. Davidson J.R., Meltzer-Brody S.E. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J. Clin. Psychiatry. 60(Suppl. 7):1999;4-9
12. DeLoach L.J., Higgins M.S., Caplan A.B., Stiff J.L. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth. Analg. 86:1998;102-106
13. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry. 63:2002;308-315
14. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36:2002;383-390
15. Di Nardo P.A., Barlow D.H. Syndrome and symptom co-occurrence in the anxiety disorders. Maser J.D., Cloninger C.R. Comorbidity of Mood and Anxiety Disorders. 1990;205-230 American Psychiatric Press, Washington, DC
16. Dunner D.L., Dunbar G.C. Optimal dose regimen for paroxetine. J. Clin. Psychiatry. 53:1992;21-26. (Suppl.)
17. Faravelli C., Cosci F., Ciampelli M., Scarpato M.A., Spiti R., Ricca V. A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother. Psychosom. 72:2003;95-101
18. Fava M. Somatic symptoms, depression, and antidepressant treatment. J. Clin. Psychiatry. 63:2002;305-307
19. Fava M., Judge R., Hoog S.L., Nilsson M.E., Koke S.C. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psychiatry. 61:2000;863-867
20. Fawcett J., Barkin R.L. Efficacy issues with antidepressants. J. Clin. Psychiatry. 58(Suppl. 6):1997;32-39
21. Fawcett J., Kravitz H.M. Anxiety syndromes and their relationship to depressive illness. J. Clin. Psychiatry. 44:1983;8-11
22. Fawcett J., Scheftner W.A., Fogg L., Clark D.C., Young M.A., Hedeker D., Gibbons R. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry. 147:1990;1189-1194
23. Fishbain D.A. Evidence-based data on pain relief with antidepressants. Ann. Med. 32:2000;305-316
24. Fishbain D.A., Cutler R., Rosomoff H.L., Rosomoff R.S. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin. J. Pain. 13:1997;116-137
25. Gadde K.M., Parker C.B., Maner L.G., Wagner H.R., Logue E.J., Drezner M.K., Krishnan K.R. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. 9:2001;544-551
26. Garrison G.D., Levin G.M. Factors affecting prescribing of the newer antidepressants. Ann. Pharmacother. 34:2000;10-14
27. Glassman A.H. Cardiovascular effects of antidepressant drugs: updated. J. Clin. Psychiatry. 59(Suppl. 15):1998;13-18
28. Goldstein D.J., Mallinckrodt C., Lu Y., Demitrack M.A. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry. 63:2002;225-231
29. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 2004;. (in press)
30. Greden J.F. The burden of disease for treatment-resistant depression. J. Clin. Psychiatry. 62(Suppl. 16):2001;26-31
31. Grunhaus L., Harel Y., Krugler T., Pande A.C., Haskett R.F. Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clin. Neuropharmacol. 11:1988;454-461
32. Gumnick J.F., Nemeroff C.B. Problems with currently available antidepressants. J. Clin. Psychiatry. 61(Suppl. 10):2000;5-15
33. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. 1976;National Institutes of Mental Health, Rockville, MD
34. Hamilton M. Assessment of anxiety states by rating. Br. J. Med. Psychol. 32:1959;50-55
35. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62
36. Hirschfeld R.M. Clinical importance of long-term antidepressant treatment. Br. J. Psychiatry. (Suppl. 42):2001;S4-S8
37. Kennedy S.H., Dickens S.E., Eisfeld B.S., Bagby R.M. Sexual dysfunction before antidepressant therapy in major depression. J. Affect. Disord. 56:1999;201-208
38. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 51:1994;8-19
39. Kirmayer L.J., Robbins J.M., Dworkind M., Yaffe M.J. Somatization and the recognition of depression and anxiety in primary care. Am. J. Psychiatry. 150:1993;734-741
40. Kroenke K., Price R.K. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch. Intern. Med. 153:1993;2474-2480
41. Labbate L.A., Grimes J., Hines A., Oleshansky M.A., Arana G.W. Sexual dysfunction induced by serotonin reuptake antidepressants. J. Sex Marital Ther. 24:1998;3-12
42. Leon A.C. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J. Clin. Psychiatry. 62(Suppl. 4):2001;12-16
43. Lepine J.P., Gastpar M., Mendlewicz J., Tylee A. Depression in the community: the first pan-European Study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12:1997;19-29
44. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. 26:2001;30-36
45. Mace S., Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin. Pharmacother. 1:2000;917-933
46. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 11:2001;9-21
47. Mallinckrodt C.H., Clark W.S., David S.R. Type I error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via Last Observation Carried Forward. Drug Inf. J. 35:2001;1215-1225
48. McGahuey C.A., Gelenberg A.J., Laukes C.A., Moreno F.A., Delgado P.L., McKnight K.M., Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther. 26:2000;25-40
49. Millan M.J. Descending control of pain. Prog. Neurobiol. 66:2002;355-474
50. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J. Clin. Psychiatry. 62(Suppl. 3):2001;10-21
51. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389
52. Montgomery S.A., Kasper S. Depression: a long-term illness and its treatment. Int. Clin. Psychopharmacol. 13(Suppl. 6):1998;S23-S26
53. Murray C.J.L., Lopez A.D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. 1996;Harvard Univ. Press, Cambridge, MA
54. Nelson J.C., Mazure C.M., Bowers M.B. Jr., Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 48:1991;303-307
55. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., Tran P.V. Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. 36:2002;106-132
56. Nierenberg A.A., Wright E.C. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry. 60(Suppl. 22):1999;7-11
57. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25:1995;1171-1180
58. PDR Physicians' Desk Reference. 56th edn.:2002;Medical Economics, Montvale, NJ
59. Piazza L.A., Markowitz J.C., Kocsis J.H., Leon A.C., Portera L., Miller N.L., Adler D. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am. J. Psychiatry. 154:1997;1757-1759
60. Potter W.Z., Rudorfer M.V., Manji H. The pharmacologic treatment of depression. N. Engl. J. Med. 325:1991;633-642. (Aug. 29)
61. Raskin J., Goldstein D.J., Mallinckrodt C.H., Ferguson M. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry. 64:2003;1237-1244
62. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., Beasley C.M. Jr., Michelson D., Roback P., Sundell K. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry. 155:1998;1247-1253
63. Rosenbaum J.F., Hylan T.R. Costs of depressive disorders. Maj M., Sartorius N. Depressive Disorders. 1999;401-449 Wiley, New York, NY
64. Rouillon F. Anxiety with depression: a treatment need. Eur. Neuropsychopharmacol. 9(Suppl. 3):1999;S87-S92
65. Schwarz R., Gunzelmann T., Hinz A., Brahler E. Anxiety and depression in the general population over 60 years old. Dtsch. Med. Wochenschr. 126:2001;611-615. (May 25)
66. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int. Clin. Psychopharmacol. 11(Suppl. 3):1996;89-95
67. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 59(Suppl. 20):1998;22-33
68. Simon G.E., Von Korff M., Piccinelli M., Fullerton C., Ormel J. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med. 341:1999;1329-1335. (Oct. 28)
69. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400
70. Stahl S.M. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J. Clin. Psychiatry. 60:1999;213-214
71. Stahl S.M., Entsuah R., Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry. 52:2002;1166-1174
72. Steffens D.C., Krishnan K.R., Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress. Anxiety. 6:1997;10-18
73. Stein M.B., Kirk P., Prabhu V., Grott M., Terepa M. Mixed anxiety-depression in a primary-care clinic. J. Affect. Disord. 34:1995;79-84. (May 17)
74. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry. 59:1998;502-508
75. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 178:2001;234-241
76. Thompson W.L., Brunelle R.L., Enas G.G., et al. Routine Laboratory Tests in Clinical Trials. 1990;1-63 Eli Lilly and Company, Indianapolis, IN. Data on File
77. Tran P.V., Bymaster F.P., McNamara R.K., Potter W.Z. Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol. 23:2003;78-86
78. Wong D.T., Bymaster F.P. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog. Drug Res. 58:2002;169-222